---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-022952"
form_type: "8-K"
ticker: "FLNA"
cik: "0001069530"
company_name: "FILANA THERAPEUTICS, INC."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:29:42.484973+00:00"
event_type: "litigation"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cassava Sciences settles shareholder derivative suit; CEO bonus now tied to FDA approval of simufilam

## Summary
- Settlement modifies CEO Remi Barbier's $74.9M bonus: payment requires FDA approval of simufilam or recalculation upon sale.
- Corporate governance reforms: new Compensation Disclosure Committee, retention of compensation consultant by board.
- Court approval hearing set for Sept 9, 2024; settlement includes dismissal of derivative claims with prejudice.
- Cassava also achieved removal of non-employee directors from bonus plan and appointment of three independent directors.

## SEC filing metadata
- accession: 0001437749-24-022952
- form_type: 8-K
- ticker: FLNA
- cik: 0001069530
- company_name: FILANA THERAPEUTICS, INC.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: litigation
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069530/000143774924022952/0001437749-24-022952-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069530/000143774924022952/sava20240716_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-022952
- JSON: https://secwatch.observer/filing/0001437749-24-022952.json
- Plain text: https://secwatch.observer/filing/0001437749-24-022952.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.